Abstract
Objective: The objective of the study was to evaluate and compare the effect of insulin sensitizers i.e. metformin and myoinositol on anthropometric parameters in patients of the Polycystic ovarian syndrome (PCOS).Methods: A prospective, open-labeled, randomized, comparative, clinical study was conducted on 60 patients. The patients were randomly divided into two groups of 30 each to receive either of the following two treatments: group A: Tablet myoinositol 1g twice daily. group B: Tablet metformin 500 mg thrice daily for 24 w. Anthropometric parameters were assessed by measuring body weight, Body mass index (BMI), waist circumference, hip circumference, waist-hip ratio (WHR) at baseline and subsequently at the end of 12 w and 24 w.Results: In both the groups, there was a statistically significant improvement in over a period of 24 w. In group A, the values for weight at baseline, 12 w and 24 w expressed in mean±SEM are 63.96±.90, 62.33±.88 and 61.20±.85 while in group B the values were 63.58±1.88, 62.26±1.74 and 60.86±1.65. In group A, the values for BMI at baseline, 12 w and 24 w were 26.45±.41, 25.78±.42 and 25.31±.40 while in group B the values were 26.09±.76, 25.53±.71 and 24.96±.68 respectively. In group A, WHR values were 0.79±.007, 0.78±.007 and 0.78±.007 while in group B 0.79±.010, 0.79±0.108, 0.79±.011 at baseline, 12 w and 24 w respectively. However, on comparing both the groups at 12 and 24 w, no statistically significant difference was observed in all the parameters.Conclusion: There was a definite improvement in anthropometric parameters with both metformin and myoinositol but on comparing these drugs, no significant difference was observed. Thus, myoinositol can also be used as an alternative to metformin for the treatment of PCOS.
Highlights
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among women of reproductive age
Prevalence of Polycystic ovarian syndrome (PCOS) is increased in overweight and obese women when compared to their lean counterparts
Abdominal fat distribution is measured by Waist-hip ratio (WHR) which gets altered in insulin resistance
Summary
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among women of reproductive age. More than 30% of women with PCOS are obese (body mass index–BMI>30 kg/m2), reflecting primarily visceral adiposity [1]. Obesity is a prominent feature of PCOS, occurring in 40-50% of PCOS patients [2, 3]. Prevalence of PCOS is increased in overweight and obese women when compared to their lean counterparts. The prevalence rates of PCOS in underweight, normal-weight, overweight, and obese women are 8.2%, 9.8%, 9.9% and 9.0% respectively. Prevalence rates are 12.4% and 11.5% in women with BMI 35-40 kg/m2 and greater than 40 kg/m2 [4]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
